Study guide

3.3 Eligibility Verification and Trial Designs

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

3.3 Eligibility Verification and Trial Designs

Key Takeaways Explain This Topic AI

Eligibility evidence should support the investigator’s enrolment decision at the required time.

Crossover designs need control of residual effects between treatment periods.

Parallel, factorial and adaptive designs address different scientific and operational questions.

Last updated: October 2026

Eligibility Verification and Trial Designs

"Protocol creep" is the informal, gradual erosion of baseline eligibility standards by site personnel. Over time, coordinators and investigators face recruitment pressure and begin rationalizing borderline eligibility failures (e.g., enrolling a patient with diastolic blood pressure of 92 mmHg 92\text{ mmHg} 92 mmHg when the protocol cutoff is strictly < 90 mmHg <90\text{ mmHg} < 90 mmHg , or accepting lab values collected outside protocol-stipulated screening windows).

CRA Detection Techniques:

Verify source laboratory and diagnostic reports directly from central and local laboratories rather than relying on transcribed values on the eCRF.

Check timestamps: Ensure all baseline laboratory draws, imaging scans, and washouts were completed within the exact screening window specified in the protocol.

Audit the Screening Log: Check every screen failure.

If a site reports zero screen failures across dozens of screened subjects, investigate whether the site is improperly enrolling borderline candidates or failing to log failed screenings.

Immediate Actions upon Discovering an Ineligible Enrolled Subject

Assess Immediate Subject Safety: Determine whether exposure to the investigational product creates acute health risks.

Notify the Principal Investigator: Highlight the exact protocol violation and document the discussion.

Alert the Sponsor Medical Monitor: Immediately report the deviation to the sponsor's clinical team and medical monitor.

Evaluate Withdrawal Criteria: Consult protocol stopping rules to confirm if the subject must be discontinued from IP dosing immediately.

Document the Major Deviation: File a formal protocol deviation report in the eCRF system and the Investigator Site File (ISF).

Study Designs, Randomization & Bias Control Strategies

Note

ICH E9 ("Statistical Principles for Clinical Trials") establishes the international scientific standard for controlling operational and statistical bias. A trial's internal validity hinges on its ability to isolate the true pharmacological effect of an investigational product from confounding variables, investigator expectations, and participant subjective perception.

Selecting an appropriate study architecture requires balancing statistical efficiency, patient safety, disease natural history, and operational feasibility. For a Clinical Research Associate, understanding the structural mechanics of clinical study designs and their built-in bias defenses is crucial for auditing randomization compliance, safeguarding masking, and monitoring emergency unblinding events.

Clinical Trial Design Architectures

Every clinical trial implements a specific structural design that dictates how subjects are exposed to investigational and control interventions over time.

Parallel Group Design

The parallel group design is the most common and robust architecture for confirmatory Phase III trials. Subjects are randomized to one of two or more distinct arms (e.g., Investigational Drug vs. Active Comparator vs. Placebo) and remain on their assigned treatment throughout the entire observation period.

Advantages: Clean, straightforward statistical analysis; no risk of carryover effects; applicable to many acute diseases (e.g., myocardial infarction, sepsis), progressive conditions (e.g., oncology), and chronic conditions.

Disadvantages: High inter-individual variability between subjects across arms, requiring relatively large sample sizes to achieve adequate statistical power.

Crossover Design

In a crossover design, each participant receives two or more treatments in sequential order separated by an intervening washout interval. In the classic 2 × 2 2 \times 2 2 × 2 design, subjects are randomized to Sequence 1 (Treatment A followed by Treatment B) or Sequence 2 (Treatment B followed by Treatment A).

Within-Subject Comparisons: Because each participant serves as their own control, between-participant variability can be reduced from the treatment comparison. This dramatically reduces the required sample size depending on within-participant variability and the design.

Essential Prerequisites: Crossover designs are generally suited to stable conditions with constant baseline symptoms (e.g., chronic stable angina, mild hypertension, asthma). They are often unsuitable when disease progression or irreversible treatment effects undermine within-participant comparisons.

The Washout Period: The interval between treatment periods must be long enough to allow all residual drug and active metabolites to clear from the body as justified in the protocol, considering elimination and persistence of biological effects and for all biological/pharmacodynamic effects to return completely to baseline.

Carryover Effect: The persistence of treatment effects from the first period into the second period. If carryover occurs, it creates a treatment-by-period interaction that can bias the treatment comparison and must be evaluated under the analysis plan.

Factorial Design ( 2 × 2 2 \times 2 2 × 2 )

A factorial design evaluates two distinct experimental interventions (e.g., Drug A and Drug B) simultaneously against control within the same patient population.

Treatment Arms: Group 1 receives Drug A + Drug B; Group 2 receives Drug A + Placebo B; Group 3 receives Placebo A + Drug B; Group 4 receives Placebo A + Placebo B.

Efficiency: Allows testing the efficacy of both drugs simultaneously with minimal sample size inflation, provided there is no pharmacological interaction between the two treatments. It also enables explicit statistical evaluation of synergy or antagonism.

Adaptive Trial Designs

Adaptive designs allow pre-specified, planned modifications to trial procedures (such as sample size re-estimation, dropping ineffective dosage arms, or enriching patient subsets based on biomarker expression) based on accrued interim data.

Governance: Adaptive changes must be pre-planned in the protocol and simulation models, and implemented under prespecified methods and suitable independent/unblinded review and access safeguards to prevent premature unblinding of sponsors or investigators.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E9 , ICH E9(R1) , ICH E8(R1) .